Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-03

Clinical Trial Update: Linagliptin as Add on to Basal Insulin in the Elderly [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating adding linagliptin to basal insulin in elderly patients with type 2 diabetes has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2018-07-03